Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 12
Submit an article Journal homepage
536
Views
28
CrossRef citations to date
0
Altmetric
Reviews

Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment

Jean Engohang-NdongKent State University at Tuscarawas, Department of Biological Sciences, 330 University Dr. NE; New Philadelphia, OH 44663, USA+1 001 330 308 7458; +1 001 330 339 3321; [email protected];Département de Biologie, Université des Sciences et Techniques de Masuku, B.P. 901; Franceville, Gabon+241 07 17 33 61; +241 67 74 49
, PhD
Pages 1789-1800 | Published online: 19 Sep 2012

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sandeep Singh, Gurpuneet Kaur, Veenu Mangla & Manish K. Gupta. (2015) Quinoline and quinolones: promising scaffolds for future antimycobacterial agents. Journal of Enzyme Inhibition and Medicinal Chemistry 30:3, pages 492-504.
Read now
Giovanni Sotgiu, Emanuele Pontali, Rosella Centis, Lia D’Ambrosio & Giovanni Battista Migliori. (2015) Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Review of Anti-infective Therapy 13:3, pages 305-315.
Read now

Articles from other publishers (26)

Gautam Kumar & Amrutha C. (2023) Natural products and their analogues acting against Mycobacterium tuberculosis : A recent update . Drug Development Research.
Crossref
Aditi Chauhan, Manoj Kumar, Awanish Kumar & Kajal Kanchan. (2021) Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs. Life Sciences 274, pages 119301.
Crossref
Ken-ichi Kimura. (2019) Studies of novel bioprobes isolated from rare natural sources using mutant yeasts. The Journal of Antibiotics 72:8, pages 579-589.
Crossref
Maddie R. Lemieux, Shajila Siricilla, Katsuhiko Mitachi, Shakiba Eslamimehr, Yuehong Wang, Dong Yang, Jeffrey D. Pressly, Ying Kong, Frank Park, Scott G. Franzblau & Michio Kurosu. (2018) An antimycobacterial pleuromutilin analogue effective against dormant bacilli. Bioorganic & Medicinal Chemistry 26:17, pages 4787-4796.
Crossref
V. E. Kataev, R. N. Khaybullin, B. F. Garifullin & R. R. Sharipova. (2018) New Targets for Growth Inhibition of Mycobacterium tuberculosis: Why Do Natural Terpenoids Exhibit Antitubercular Activity?. Russian Journal of Bioorganic Chemistry 44:4, pages 438-452.
Crossref
Ben Gold & Carl Nathan. 2017. Tuberculosis and the Tubercle Bacillus. Tuberculosis and the Tubercle Bacillus 317 360 .
Ben Gold & Carl Nathan. (2017) Targeting Phenotypically Tolerant Mycobacterium tuberculosis . Microbiology Spectrum 5:1.
Crossref
Laurent Maveyraud. 2017. Drug Design: Principles and Applications. Drug Design: Principles and Applications 89 112 .
Chitra Rani & Inshad Ali Khan. (2016) UDP-GlcNAc pathway: Potential target for inhibitor discovery against M. tuberculosis. European Journal of Pharmaceutical Sciences 83, pages 62-70.
Crossref
Alvin Teo & David Roper. (2015) Core Steps of Membrane-Bound Peptidoglycan Biosynthesis: Recent Advances, Insight and Opportunities. Antibiotics 4:4, pages 495-520.
Crossref
Deepak Kumar, Beena Negi & Diwan S Rawat. (2015) The anti-tuberculosis agents under development and the challenges ahead. Future Medicinal Chemistry 7:15, pages 1981-2003.
Crossref
Dulce Mata-Espinosa, Gloria María Molina-Salinas, Jorge Barrios-Payán, Gabriel Navarrete-Vázquez, Brenda Marquina, Octavio Ramos-Espinosa, Estela Isabel Bini, Isabel Baeza & Rogelio Hernández-Pando. (2015) Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis. Pulmonary Pharmacology & Therapeutics 32, pages 7-14.
Crossref
Lia D'Ambrosio, Rosella Centis, Giovanni Sotgiu, Emanuele Pontali, Antonio Spanevello & Giovanni Battista Migliori. (2015) New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Research 1:1, pages 00010-2015.
Crossref
Shajila Siricilla, Katsuhiko Mitachi, Bajoie Wan, Scott G Franzblau & Michio Kurosu. (2014) Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors. The Journal of Antibiotics 68:4, pages 271-278.
Crossref
Takeshi Nakaya, Akira Matsuda & Satoshi Ichikawa. (2015) Design, synthesis and biological evaluation of 5′-C-piperidinyl-5′-O-aminoribosyluridines as potential antibacterial agents. Organic & Biomolecular Chemistry 13:28, pages 7720-7735.
Crossref
Monika Jankute, Shipra Grover, Helen L. Birch & Gurdyal S. Besra. 2014. Molecular Genetics of Mycobacteria. Molecular Genetics of Mycobacteria 535 557 .
Andrej Trauner, Christopher M. Sassetti & Eric J. Rubin. 2014. Molecular Genetics of Mycobacteria. Molecular Genetics of Mycobacteria 493 509 .
Andrej Trauner, Christopher M. Sassetti & Eric J. Rubin. (2014) Genetic Strategies for Identifying New Drug Targets. Microbiology Spectrum 2:4.
Crossref
Monika Jankute, Shipra Grover, Helen L. Birch & Gurdyal S. Besra. (2014) Genetics of Mycobacterial Arabinogalactan and Lipoarabinomannan Assembly. Microbiology Spectrum 2:4.
Crossref
Yong Cheng, Garrett C. Moraski, Jeffrey Cramer, Marvin J. Miller & Jeffrey S. Schorey. (2014) Bactericidal Activity of an Imidazo[1, 2-a]pyridine Using a Mouse M. tuberculosis Infection Model. PLoS ONE 9:1, pages e87483.
Crossref
Robert C. Goldman. (2013) Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?. Tuberculosis 93:6, pages 569-588.
Crossref
Yoshimasa Ishizaki, Chigusa Hayashi, Kunio Inoue, Masayuki Igarashi, Yoshiaki Takahashi, Venugopal Pujari, Dean C. Crick, Patrick J. Brennan & Akio Nomoto. (2013) Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core, Catalyzed by the GlcNAc-1-phosphate Transferase WecA, by the Novel Caprazamycin Derivative CPZEN-45. Journal of Biological Chemistry 288:42, pages 30309-30319.
Crossref
Giovanna Riccardi, Maria Rosalia Pasca, Laurent Roberto Chiarelli, Giulia Manina, Andrea Mattevi & Claudia Binda. (2013) The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Applied Microbiology and Biotechnology 97:20, pages 8841-8848.
Crossref
Johanna J Salomon, Pauline Galeron, Nanette Schulte, Paul R Morow, Diana Severynse-Stevens, Hanno Huwer, Nicole Daum, Claus-Michael Lehr, Anthony J Hickey & Carsten Ehrhardt. (2013) Biopharmaceutical in vitro characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis . Therapeutic Delivery 4:8, pages 915-923.
Crossref
Domingo PalmeroViviana Ritacco. (2013) Clinical Management of Drug-Resistant Tuberculosis in Resource Constrained Settings. Clinical Medicine Insights: Therapeutics 5, pages CMT.S6560.
Crossref
Judith F. Daar. (2003) The Prospect of Human Cloning: Improving Nature or Dooming the Species?. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.